B-cell reduction using CD37-specific and CD20-specific binding molecules
Details for Australian Patent Application No. 2006272555 (hide)
International Classifications
Event Publications
31 January 2008 PCT application entered the National Phase
PCT publication WO2007/014278 Priority application(s): WO2007/014278
21 April 2011 Assignment before Grant
Trubion Pharmaceuticals, Inc. The application has been assigned to Emergent Product Development Seattle LLC
8 March 2012 Application Accepted
Published as AU-B-2006272555
5 July 2012 Standard Patent Sealed
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2006272567-Antibody profiles characteristic of tuberculosis state
2006272553-Compressive surfaces for ultrasonic tissue scanning
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
![](/images/main/3dbox_small.png)
- Editable Word format reports
- For IP Professionals
- Multiuser